Table 3 Distribution of KIR/HLA-C combinations in CRC patients, local healthy samples and Italian controls
From: Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage
KIR genes and HLA ligands | CRC patients (NÂ =Â 52) | Local controls (NÂ =Â 58) | p valuea | OR | Fasano, 2014 (NÂ =Â 270) | p valuea | OR | |||
|---|---|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | |||||
2DL1 HLA-C2+ | 34 | 65.4 | 43 | 74.1 | NS | Â | 187 | 69.3 | NS | Â |
2DL1 HLA-C2− | 17 | 32.7 | 13 | 22.4 | NS |  | 74 | 27.4 | NS |  |
2DL2 HLA-C1+ | 28 | 53.8 | 26 | 44.8 | NS | Â | 113 | 41.9 | NS | Â |
2DL2 HLA-C1/C1 | 11 | 21.2 | 5 | 8.6 | NS | Â | Â | Â | Â | Â |
2DL2 HLA-C1− | 3 | 5.8 | 11 | 19.0 | 0.047 | 0.2616 | 43 | 16.0 | 0.08 |  |
2DL3 HLA-C1+ | 40 | 76.9 | 35 | 60.3 | NS | Â | 183 | 67.8 | NS | Â |
2DL3 HLA-C1− | 6 | 11.5 | 11 | 19.0 | NS |  | 51 | 18.8 | NS |  |
2DS1 HLA-C2+ | 13 | 25.0 | 22 | 37.9 | NS | Â | 68 | 25.2 | NS | Â |
2DS1 HLA-C2− | 7 | 13.5 | 6 | 10.3 | NS |  | 29 | 10.7 | NS |  |
2DS2 HLA-C1+ | 30 | 57.7 | 24 | 41.4 | NS | Â | 112 | 41.5 | 0.033 | 1.9237 |
2DS2 HLA-C1− | 3 | 5.8 | 8 | 13.8 | NS |  | 44 | 16.3 | 0.05 | 0.3145 |
2DS2 AND 2DS3 HLA-C1+ | 16 | 30.8 | 14 | 24.1 | NS | Â | Â | Â | Â | Â |
2DS2+Â , KIR2DL2 or 2DL3+Â , C group 1+ | 30 | 57.7 | 23 | 39.7 | 0.08 | Â | Â | Â | Â | Â |
2DL2 and 2DS2+ , C group 1 − | 2 | 3.8 | 8 | 13. 8 | 0.09 |  |  |  |  |  |